Literature DB >> 2056064

Spiral gradient endpoint method compared to standard agar dilution for susceptibility testing of anaerobic gram-negative bacilli.

G B Hill1.   

Abstract

More efficient and reproducible alternative methods of performing agar dilution susceptibility testing are desirable, particularly for anaerobic bacteria. Anaerobes generally grow more reliably on solid media than they do in broth microdilution wells. A new method, the revised spiral gradient endpoint (SGE) method, was evaluated against the standard agar dilution (SAD) method by using a wide variety of anaerobic gram-negative bacilli (161 strains) and eight antimicrobial agents. For the SGE method, a spiral plater was used to set up a concentration gradient of an antimicrobial agent within an agar plate across which bacterial strains were inoculated as radial streaks. After incubation, the MIC of the antimicrobial agent was calculated from the radial endpoint location where bacterial growth ceased along the streak. The MICs for 90% of strains tested (in micrograms per milliliter) and the cumulative percentages of susceptible strains at the breakpoints for the SGE and SAD methods, respectively, and for all 161 strains were as follows: for metronidazole, 2 and 100 versus 2 and 100; for imipenem, 1 and 99 versus 0.5 and 98; for ampicillin-sulbactam, 8 and 97 versus 8 and 98; for clindamycin, 4 and 90 versus 4 and 91; for cefoxitin, 32 and 95 versus 32 and 95; for mezlocillin, 256 and 88 versus greater than 128 and 86; for ampicillin, greater than or equal to 256 and 51 versus greater than 64 and 51; and for penicillin (in units per milliliter), greater than or equal to 512 and 71 versus greater than 64 and 65. The excellent agreement of these data and the greater sensitivity reproducibility, and efficiency of the revised SGE method warrant further evaluations. Assuming that these advantages are confirmed, the revised SGE method should be a useful alternative test method when detailed susceptibility data are desired.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056064      PMCID: PMC269918          DOI: 10.1128/jcm.29.5.975-979.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  National Committee for Clinical Laboratory Standards agar dilution susceptibility testing of anaerobic gram-negative bacteria.

Authors:  W J Brown
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

2.  In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.

Authors:  H M Wexler; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.

Authors:  N A Cornick; G J Cuchural; D R Snydman; N V Jacobus; P Iannini; G Hill; T Cleary; J P O'Keefe; C Pierson; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1990-06       Impact factor: 5.790

4.  Development and evaluation of the spiral gradient endpoint method for susceptibility testing of anaerobic gram-negative bacilli.

Authors:  G B Hill; S Schalkowsky
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

5.  Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.

Authors:  J P O'Keefe; F R Venezio; C A DiVincenzo; K L Shatzer
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

6.  Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.

Authors:  E J Goldstein; D M Citron
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

7.  In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

Authors:  H M Wexler; B Harris; W T Carter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.